Optimal IFN-free therapy in treatment-naïve patients with HCV genotype 1 infection.

Abstract excerpt

There has been a revolution in the treatment of chronic hepatitis C. Several oral regimens combining direct-acting antivirals (DAAs) from different families [NS5B nucleotide inhibitors, NS5B non-nucleoside inhibitors, NS5A replication complex inhibitors and NS3/4A protease inhibitors (PI)] are under development. These regimens result in an increase in sustained virological response (SVR) rates to above 90% and...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Antiviral Agents
• Share to Drug Therapy, Combination